InsidersTradesSigma
Track the Inmune Bio, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Inmune Bio, Inc. has published 47 reports. Market capitalisation: €64.7m. The latest transaction was filed on 7 July 2026 (Levée d'options). Among the most active insiders: Moss David J. Every trade is accessible without an account.
47
Insider Decl.
n/a
Thresholds
€1m
13 ops.
Buy Volume
€2m
17 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Inmune Bio, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$7.00.
46Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 7 July 2026
Declarations47 total
9,014 shares@ US$1.400.022% mcap0.9% of flowCommon StockSEC:0001213900-26-075736:0
7,211 shares@ US$1.400.017% mcap1.2% of flowCommon StockSEC:0001213900-26-075737:0
14,801 shares@ US$1.400.036% mcap2.9% of flowCommon StockSEC:0001213900-26-075738:0
10,000 shares@ US$5.28684.0% of flowCommon StockSEC:0001213900-24-083348:0
Canonical exit: 29 Dec 2024 (T+90)
15,380 shares@ US$6.3754.1% of flowCommon StockSEC:0001213900-24-079121:0
Canonical exit: 11 Dec 2024 (T+90)
7,690 shares@ US$6.3753.8% of flowCommon StockSEC:0001213900-24-079119:0
Canonical exit: 11 Dec 2024 (T+90)
5,000 shares@ US$7.275.6% of flowCommon StockSEC:0001213900-24-055920:0
Canonical exit: 23 Sept 2024 (T+90)
29,603 shares@ US$8.3238.4% of flowCommon StockSEC:0001213900-24-035720:0
Canonical exit: 18 Jul 2024 (T+90)
18,028 shares@ US$8.326.6% of flowCommon StockSEC:0001213900-24-035722:0
Canonical exit: 18 Jul 2024 (T+90)
18,028 shares@ US$8.3212.0% of flowCommon StockSEC:0001213900-24-035723:0
Canonical exit: 18 Jul 2024 (T+90)
14,423 shares@ US$8.3215.6% of flowCommon StockSEC:0001213900-24-035721:0
Canonical exit: 18 Jul 2024 (T+90)
14,423 shares@ US$8.3215.6% of flowCommon StockSEC:0001213900-24-035472:0
29,603 shares@ US$8.3238.4% of flowCommon StockSEC:0001213900-24-035471:0
18,028 shares@ US$8.326.6% of flowCommon StockSEC:0001213900-24-035474:0
18,028 shares@ US$8.3212.0% of flowCommon StockSEC:0001213900-24-035473:0
7,000 shares@ US$6.957.6% of flowCommon StockSEC:0001213900-23-085758:0
Canonical exit: 8 Feb 2024 (T+90)
10,000 shares@ US$11.00853.9% of flowCommon StockSEC:0001213900-23-057083:0
2,500 shares@ US$6.4251.3% of flowCommon StockSEC:0001213900-23-021235:0
Canonical exit: 15 Jun 2023 (T+90)
7,700 shares@ US$6.276.1% of flowCommon StockSEC:0001213900-22-030208:0
Canonical exit: 24 Aug 2022 (T+90)
6,300 shares@ US$6.413.1% of flowCommon StockSEC:0001213900-22-030210:0
Canonical exit: 24 Aug 2022 (T+90)
17,793 shares@ US$8.4318.3% of flowCommon StockSEC:0001213900-22-014504:0
23,590 shares@ US$8.4339.2% of flowCommon StockSEC:0001213900-22-014509:0
17,793 shares@ US$8.43100.0% of flowCommon StockSEC:0001213900-22-014499:0
23,724 shares@ US$8.4314.8% of flowCommon StockSEC:0001213900-22-014507:0
2,500 shares@ US$13.558.3% of flowCommon StockSEC:0001213900-21-060386:0
Canonical exit: 15 Feb 2022 (T+90)
25 of 47 declarations
关于 Inmune Bio, Inc.
INmune Bio, Inc.是一家在美国上市的临床阶段生物技术公司，在纳斯达克交易，股票代码为INMB。公司总部位于美国佛罗里达州博卡拉顿，专注于开发重新编程先天免疫系统的免疫疗法，采用精准医疗方法，旨在解决具有高度未满足医疗需求的严重炎症和免疫介导疾病。公司成立于2015年，其核心理念是利用人体自身的先天免疫反应，而非简单地抑制疾病症状。（[inmunebio.com](https://www.inmunebio.com/index.php/about-us?utm_source=openai)) INmune Bio最初以免疫肿瘤学公司起家，此后已扩展到神经炎症和罕见炎症性疾病领域。其主要项目包括INKmune，旨在激活某些血液恶性肿瘤和实体瘤中的NK细胞功能；INB03，另一种肿瘤学资产；以及XPro1595，一种靶向可溶性TNF的候选药物，已在阿尔茨海默病和其他神经炎症环境中进行研究。最近，该公司还重点介绍了用于隐性营养不良性大疱性表皮松解症（RDEB）的CORDStrom，表明其平台正在从肿瘤学和神经学扩展到罕见疾病生物学领域。（[inmunebio.com](https://www.inmunebio.com/index.php/about-us?utm_source=openai)) 从竞争角度来看，INmune Bio在生物技术领域最具挑战性的一个角落运营：临床阶段开发，现金消耗高，试验结果具有二元性，并且高度依赖监管里程碑。其差异化因素是科学专注。通过靶向先天免疫，该公司与许多更依赖适应性免疫或广泛抗炎机制的同行处于不同的定位。因此，对于投资者而言，该名称应被视为一个以管线驱动的生物技术故事，而非成熟的商业企业，其估值可能仍然高度受临床数据、融资条件和监管进展的影响。（[inmunebio.com](https://www.inmunebio.com/index.php/about-us?utm_source=openai)) 从地理位置上看，INmune Bio总部位于美国佛罗里达州博卡拉顿，并通过租赁当地制造空间和相关子公司活动，在英国保持运营能力。这种跨大西洋的足迹反映了其临床和制造策略的全球性。（[sec.gov](https://www.sec.gov/Archives/edgar/data/1711754/000121390026036370/ea0279078-10k_inmune.htm?utm_source=openai)) 最近的进展集中在2025年和2026年的业务更新。公司报告了阿尔茨海默病MINDFuL项目的临床进展，CORDStrom的持续推进，以及INKmune在前列腺癌中的持续评估。这些更新强化了该公司作为一家具有重要科学选择权但同时也面临巨大执行风险的后期临床生物技术公司的形象，这在美国纳斯达克上市的小盘生物技术公司中是典型的。（[nasdaq.com](https://www.nasdaq.com/press-release/inmune-bio-inc-announces-second-quarter-2025-results-provides-business-update-and?utm_source=openai))
